Boston Scientific is really feeling the effects of its month-long recall of ICDs earlier this year. Company officials anticipate the recall, a result of failing to follow protocol for notifying the U.S. Food and Drug Administration about changes to the manufacturing of the device, will cost the company $300 million in sales over the course of 2010.

But these estimates are better than the $500 million loss in sales that the company predicted at the end of the first quarter. The recent second-quarter earnings announcement also suggested the company was doing better than anticipated. It reported net sales of $1.9 billion compared to $2.1 billion for the second quarter last year.

"In CRM, we finished the quarter well ahead of where we expected to be," said Ray Elliot, president and CEO, last month in prepared remarks.
Currently, the company's revenues in cardiac rhythm management are down 11 percent compared to this time last year.

More Industry Headlines